Targeting angiogenesis in lung cancer

Seminars in Oncology

Volumn 32, Issue SUPPL. 10, 2005, Pages

  Sandler, Alan B ^a  

^a VANDERBILT INGRAM CANCER CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AE 941; ANGIOGENESIS INHIBITOR; ANTIINFECTIVE AGENT; BEVACIZUMAB; CARBOPLATIN; CYTOKINE; DOCETAXEL; EPIDERMAL GROWTH FACTOR RECEPTOR; ERLOTINIB; FLUOROURACIL; GLYCOPROTEIN; GROWTH FACTOR; MONOCLONAL ANTIBODY; N (3,3 DIMETHYL 6 INDOLINYL) 2 (4 PYRIDINYLMETHYLAMINO)NICOTINAMIDE; PACLITAXEL; PRINOMASTAT; PROTEINASE; REBIMASTAT; RH ENDOSTATIN; SORAFENIB; SUNITINIB; UNCLASSIFIED DRUG; VANDETANIB; VASCULOTROPIN; VATALANIB;

ANGIOGENESIS; CANCER SURVIVAL; CHEMOTHERAPY; CLINICAL TRIAL; DIARRHEA; HUMAN; LUNG CANCER; LUNG NON SMALL CELL CANCER; PRIORITY JOURNAL; PROGNOSIS; RASH; REVIEW; SIGNAL TRANSDUCTION; TUMOR GROWTH;

EID: 31644450227     PISSN: 00937754     EISSN: None     Source Type: Journal    
DOI: 10.1053/j.seminoncol.2005.02.008     Document Type: Article

References (53)

1. J. Folkman What is the evidence that tumors are angiogenesis dependent? J Natl Cancer Inst 82 1990 4 6
2. D. Hanahan, J. Folkman Patterns and emerging mechanisms of the angiogenic switch during tumorigenesis Cell 86 1996 353 364
3. R. Bicknell Mechanistic insights into tumor angiogenesis R.J. Bicknell C.E. Lewis N. Ferrara Tumour Angiogenesis 1997 Oxford University Press Oxford, UK 19 28
4. P. Macchiarini, G. Fontanini, M.J. Hardin Relation of neovascularisation to metastasis of non-small-cell lung cancer Lancet 340 1992 145 146
5. G. Fontanini, D. Bigini, S. Vignati Microvessel count predicts metastatic disease and survival in non-small cell lung cancer J Pathol 177 1995 57 63
6. G. Fontanini, M. Lucchi, S. Vignati Angiogenesis as a prognostic indicator of survival in non-small-cell lung carcinoma A prospective study J Natl Cancer Inst 89 1997 881 886
7. M. Lucchi, G. Fontanini, A. Mussi Tumor angiogenesis and biologic markers in resected stage I NSCLC Eur J Cardiothorac Surg 12 1997 535 541
8. T.A. D'Amico, M. Massey, J.E. Herndon 2nd A biologic risk model for stage I lung cancer Immunohistochemical analysis of 408 patients with the use of ten molecular markers J Thorac Cardiovasc Surg 117 1999 736 743
9. G. Cox, R.A. Walker, A. Andi Prognostic significance of platelet and microvessel counts in operable non-small cell lung cancer Lung Cancer 29 2000 169 177
10. K.J. O'Byrne, M.I. Koukourakis, A. Giatromanolaki Vascular endothelial growth factor, platelet-derived endothelial cell growth factor and angiogenesis in non-small-cell lung cancer Br J Cancer 82 2000 1427 1432
11. T. Yano, S. Tanikawa, T. Fujie Vascular endothelial growth factor expression and neovascularisation in non-small cell lung cancer Eur J Cancer 36 2000 601 609
12. C. Ushijima, S. Tsukamoto, K. Yamazaki High vascularity in the peripheral region of non-small cell lung cancer tissue is associated with tumor progression Lung Cancer 34 2001 233 241
13. M.I. Koukourakis, A. Giatromanolaki, P.E. Thorpe Vascular endothelial growth factor/KDR activated microvessel density versus CD31 standard microvessel density in non- small cell lung cancer Cancer Res 60 2000 3088 3095
14. N.B. Leighl, L. Paz-Ares, J.Y. Douillard Randomized phase III study of matrix metalloproteinase inhibitor BMS-275291 in combination with paclitaxel and carboplatin in advanced non-small-cell lung cancer National Cancer Institute of Canada-Clinical Trials Group Study BR.18 J Clin Oncol 23 2005 2831 2839
15. D. Bissett, K.J. O'Byrne, J. von Pawel Phase III study of matrix metalloproteinase inhibitor prinomastat in non-small-cell lung cancer J Clin Oncol 23 2005 842 849
16. A. Sandler, J. Brahmer, A. Dowlati Randomized phase II/III trial of paclitaxel (P) plus carboplatin (C) with or without bevacizumab (NSC # 704865) in patients with advanced non-squamous non-small cell lung cancer (NSCLC) An Eastern Cooperative Oncology Group (ECOG) Trial - E4599 J Clin Oncol 23 2005 1090s abstr LBA4
17. A.L. Thomas, B. Morgan, M.A. Horsfield Phase I study of the safety, tolerability, pharmacokinetics, and pharmacodynamics of PTK787/ZK 222584 administered twice daily in patients with advanced cancer J Clin Oncol 23 2005 4162 4171
18. J. Heymach, B. Johnson, J. Rowbottom A randomized, placebo-controlled phase II trial of ZD6474 plus docetaxel in patients with NSCLC J Clin Oncol 23 2005 197s abstr 3023
19. H.W. Hirte, M. Moore, L. Siu Phase I study to determine the safety and pharmacokinetics of the novel Raf kinase and VEGFR inhibitor BAY 43-9006, administered for 28 days on/7 days off in patients with advanced, refractory solid tumors Ann Oncol 16 2005 1688 1694
20. L. Rosen, R. Kurzrock, E. Jackson Safety and pharmacokinetics of AMG 706 in patients with advanced solid tumors J Clin Oncol 23 2005 195s abstr 3013
21. L. Rosen, M. Mulay, J. Long Phase I trial of SU011248, a novel tyrosine kinase inhibitor in advanced solid tumors Proc Am Soc Clin Oncol 22 2003 191 abstr 765
22. C. Lu, R. Komaki, R. Herbst A phase III study of AE-941 with induction chemotherapy (IC) and concomitant chemoradiotherapy (CRT) for stage III non-small cell lung cancer (NSCLC) (NCI T99-0046, RTOG 02-70, MDA 99-303) An interim report of toxicity and response J Clin Oncol 23 2005 656s abstr 7144
23. Y. Sun, J. Wang, Y. Liu Results of phase III trial of Endostart (rh-endostatin, YH-16) in advanced non-small cell lung cancer (NSCLC) patients J Clin Oncol 23 2005 654s abstr 7138
24. D. Ribatti The crucial role of vascular permeability factor/vascular endothelial growth factor in angiogenesis A historical review Br J Haematol 128 2005 303 309
25. F.F. Kabbinavar, J.T. Wong, R.E. Ayala The effect of antibody to vascular endothelial growth factor and cisplatin on the growth of lung tumors in nude mice Proc Am Assoc Cancer Res 36 1995 488 abstr 2906
26. A. Gossmann, T.H. Helbich, N. Kuriyama Dynamic contrast-enhanced magnetic resonance imaging as a surrogate marker of tumor response to anti-angiogenic therapy in a xenograft model of glioblastoma multiforme J Magn Reson Imaging 15 2002 233 240
27. K.J. Kim, B. Li, J. Winer Inhibition of vascular endothelial growth factor-induced angiogenesis suppresses tumour growth in vivo Nature 362 1993 841 844
28. O. Melnyk, M. Zimmerman, K.J. Kim Neutralizing anti-vascular endothelial growth factor antibody inhibits further growth of established prostate cancer and metastases in a pre- clinical model J Urol 161 1999 960 963
29. M.S. Gordon, K. Margolin, M. Talpaz Phase I safety and pharmacokinetic study of recombinant human anti-vascular endothelial growth factor in patients with advanced cancer J Clin Oncol 19 2001 843 850
30. V. Langmuir, M. Cobleigh, R. Herbst Successful long-term therapy with bevacizumab (Avastin) in solid tumors Proc Am Soc Clin Oncol 21 2002 9a abstr 32
31. D.H. Johnson, L. Fehrenbacher, W.F. Novotny Randomized phase II trial comparing bevacizumab plus carboplatin and paclitaxel with carboplatin and paclitaxel alone in previously untreated locally advanced or metastatic non-small-cell lung cancer J Clin Oncol 22 2004 2184 2191
32. J.A. Posey, T.C. Ng, B. Yang A phase I study of anti-kinase insert domain-containing receptor antibody, IMC-1C11, in patients with liver metastases from colorectal carcinoma Clin Cancer Res 9 2003 1323 1332
33. J.M. Wood Inhibition of vascular endothelial growth factor (VEGF) as a novel approach for cancer therapy Medicina (B Aires) 60 suppl 2 2000 41 47
34. R. Khosravi-Far, C.J. Der The Ras signal transduction pathway Cancer Metastasis Rev 13 1994 67 89
35. C.G. Willett, Y. Boucher, E. di Tomaso Direct evidence that the VEGF-specific antibody bevacizumab has antivascular effects in human rectal cancer Nat Med 10 2004 145 147
36. M.I. Lin, W.C. Sessa Antiangiogenic therapy Creating a unique "window" of opportunity Cancer Cell 6 2004 529 531
37. P. Dent, D.B. Reardon, J.S. Park Radiation-induced release of transforming growth factor alpha activates the epidermal growth factor receptor and mitogen-activated protein kinase pathway in carcinoma cells, leading to increased proliferation and protection from radiation- induced cell death Mol Biol Cell 10 1999 2493 2506
38. T. Akimoto, N.R. Hunter, L. Buchmiller Inverse relationship between epidermal growth factor receptor expression and radiocurability of murine carcinomas Clin Cancer Res 5 1999 2884 2890
39. D.H. Gorski, M.A. Beckett, N.T. Jaskowiak Blockage of the vascular endothelial growth factor stress response increases the antitumor effects of ionizing radiation Cancer Res 59 1999 3374 3378
40. D.H. Gorski, H.J. Mauceri, R.M. Salloum Potentiation of the antitumor effect of ionizing radiation by brief concomitant exposures to angiostatin Cancer Res 58 1998 5686 5689
41. H.J. Mauceri, N.N. Hanna, M.A. Beckett Combined effects of angiostatin and ionizing radiation in antitumour therapy Nature 394 1998 287 291
42. K.J. Williams, B.A. Telfer, S. Brave ZD6474, a potent inhibitor of vascular endothelial growth factor signaling, combined with radiotherapy Schedule-dependent enhancement of antitumor activity Clin Cancer Res 10 2004 8587 8593
43. R.S. Herbst, D.H. Johnson, E. Mininberg Phase I/II trial evaluating the anti-vascular endothelial growth factor monoclonal antibody bevacizumab in combination with the HER-1/ epidermal growth factor receptor tyrosine kinase inhibitor erlotinib for patients with recurrent non-small-cell lung cancer J Clin Oncol 23 2005 2544 2555
44. D.W. Davis, D.J. McConkey, J.L. Abbruzzese Surrogate markers in antiangiogenesis clinical trials Br J Cancer 89 2003 8 14
45. G. Bocci, S. Man, S.K. Green Increased plasma vascular endothelial growth factor (VEGF) as a surrogate marker for optimal therapeutic dosing of VEGF receptor-2 monoclonal antibodies Cancer Res 64 2004 6616 6625
46. J.C. Yang, L. Haworth, R.M. Sherry A randomized trial of bevacizumab, an anti-vascular endothelial growth factor antibody, for metastatic renal cancer N Engl J Med 349 2003 427 434
47. C. Kalka, H. Masuda, T. Takahashi Vascular endothelial growth factor (165) gene transfer augments circulating endothelial progenitor cells in human subjects Circ Res 86 2000 1198 1202
48. L.V. Beerepoot, N. Mehra, J.S. Vermaat Increased levels of viable circulating endothelial cells are an indicator of progressive disease in cancer patients Ann Oncol 15 2004 139 145
49. F. Bertolini, W. Mingrone, A. Alietti Thalidomide in multiple myeloma, myelodysplastic syndromes and histiocytosis. Analysis of clinical results and of surrogate angiogenesis markers Ann Oncol 12 2001 987 990
50. A. Jackson, G.C. Jayson, K.L. Li Reproducibility of quantitative dynamic contrast-enhanced MRI in newly presenting glioma Br J Radiol 76 2003 153 162
51. S. Wedge, D. Checkley, J. Tessler Dynamic contrast-enhanced MRI study of human tumor xenografts treated with the VEGF signaling inhibitor ZD6474 Proc Am Assoc Cancer Res 42 2001 abstr 581
52. B. Morgan, A.L. Thomas, J. Drevs Dynamic contrast-enhanced magnetic resonance imaging as a biomarker for the pharmacological response of PTK787/ZK 222584, an inhibitor of the vascular endothelial growth factor receptor tyrosine kinases, in patients with advanced colorectal cancer and liver metastases Results from two phase I studies J Clin Oncol 21 2003 3955 3964
53. J.H. Schiller, D. Harrington, C.P. Belani Comparison of four chemotherapy regimens for advanced non-small-cell lung cancer N Engl J Med 346 2002 92 98